Targeted Therapies: Trastuzumab and Beyond (continued)

Rilotumumab targets the c-met receptor’s activating ligand, the hepatocyte growth factor; data published in 2012 from a phase 2 randomized trial of epirubicin, cisplatin, and capecitabine either with or without rilotumumab, found superior PFS (5.6 vs. 4.2 months) among patients with metastatic gastric or gastroesophageal cancers and “a trend toward improvement of OS (11.1 months vs. 8.9 months; HR, 0.73; 94% CI: 0.53-1.01)” with rilotumumab administration, Dr. Bendell reported.8  Notably, among the 42% of patients in that trial who were found to overexpress c-met, OS was superior among patients receiving rilotumumab (11.1 months vs. 5.7 months; HR, 0.29; 95% CI: 0.11-0.76), Dr. Bendell was quick to add.8  


Continue Reading

The 2013 Gastrointestinal Cancers Symposium is co-sponsored by the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO).


References

1. Wang KK. Screening for esophageal adenocarcinoma. 2013 Gastrointestinal Cancers Symposium Proceedings. http://gicasym.asco.org/sites/gicasym.org/files/gis00113000016.pdf. Accessed Jan. 27, 2013.

2. Tomizawa Y, Wang KK. Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):59-73.

3. US National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) Stat Fact Sheet: Esophagus. http://seer.cancer.gov/statfacts/html/esoph.html. Accessed Jan. 24, 2013.

4. US National Cancer Institute (NCI). Esophageal cancer treatment (PDQ). Revised Dec. 13, 2012. http://www.cancer.gov/cancertopics/pdq/treatment/esophageal/Patient/page1. Accessed Jan. 28, 2013.

5. Ford H, Marshall A, Wadsley J, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma (Abstract LBA4). 2013 Gastrointestinal Cancers Symposium. J Clin Oncol. 2012; 30 (suppl 34; abstr LBA4). http://gicasym.asco.org/content/105311-133. Accessed Jan. 25, 2013.

6. Palta M, Willett CG, Czito B. Neoadjuvant chemotherapy or chemoradiotherapy in resectable esophageal cancer: a lot of data, little clarity. 2013 Gastrointestinal Cancers Symposium. http://gicasym.asco.org/neoadjuvant-chemotherapy-or-chemoradiotherapy-resectable-esophageal-cancer-lot-data-little-clarity. Accessed Jan. 27, 2013.

7. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681-692.

8. Bendell J. Overview of targeted therapies for esophageal and gastric cancers. 2013 Gastrointestinal Cancers Symposium Proceedings. http://gicasym.asco.org/sites/gicasym.org/files/gis00113000026.pdf. Accessed Jan. 26, 2013.

9. Yoon HH, Shi Q, Sukov WR, et al. HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods (Abstract 2). 2013 Gastrointestinal Cancers Symposium. J Clin Oncol. 2012; 30 (suppl 34; abstr 2). http://gicasym.asco.org/content/105406-133. Accessed Jan. 27, 2013.